| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000033201 |
| Receipt No. | R000037856 |
| Official scientific title of the study | Safety assessment study on excessive intake of test supplement -A randomized, double blind, placebo controlled, parallel study- |
| Date of disclosure of the study information | 2018/07/01 |
| Last modified on | 2019/01/04 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Safety assessment study on excessive intake of test supplement
-A randomized, double blind, placebo controlled, parallel study- |
|
| Title of the study (Brief title) | Safety assessment study on excessive intake of test supplement | |
| Region |
|
|
| Condition | ||
| Condition | Healthy volunteer | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aimed to verify the safety assessment on test supplement, 5-fold quantity of recommended daily intake, for consecutive 4 weeks |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Safety assessment on ingestion of test supplement, 5-fold quantity of recommended daily intake, for consecutive 4 weeks. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of test supplement, 5-fold quantity of recommended daily intake, for 4 weeks | |
| Interventions/Control_2 | Intake of placebo, for 4 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Healthy male and female from 20 to 65 years of age | |||
| Key exclusion criteria | 1.Subjects who have judged to have problems with participation in examination due to clinical laboratory test values or cardiorespiratory abnormality
2.Subjects who are at risk of developing allergy in relation to the test supplement. 3.Subjects who have a disease requiring regular medication. Subjects who have a history of serious illness requiring medication treatment 4.Subjects whose clinical laboratory values and measured values before ingestion are significantly out of the reference range 5.Subjects who are participating in other clinical trials when start of the examination period 6.Subjects who intend to become pregnant or lactating 7.Subjects who are judged as unsuitable for the study by background survey results 8.Subjects who are judged as unsuitable for the study by the principal doctor |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Kei Yui |
| Organization | FANCL Corporation |
| Division name | Research Institute |
| Address | Kamishinano 12-13, Totsuka-ku, Yokohama, Kanagawa |
| TEL | 045-820-3659 |
| tsubokawa_masaya@fancl.co.jp | |
| Public contact | |
| Name of contact person | Tomohiro Sugino |
| Organization | Soiken Inc. |
| Division name | Representative Director |
| Address | Senri Life Science Center 13F, 1-4-2 Shin-senrihigashimachi, Toyonaka, Osaka |
| TEL | 06-6871-8888 |
| Homepage URL | |
| sugino@soiken.com | |
| Sponsor | |
| Institute | FANCL Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | FANCL Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037856 |